Podcasts about royalties

Sting is being sued by his ex-bandmates for millions in unpaid royalties, Radiohead surprise fans by announcing their first official tour in over 7 years, the Sex Pistols are forced to cancel their upcoming North & South American tour dates due to an unexpected injury in the band, the Ronnie James Dio Stand Up and Shout for Cancer fund announces their annual Bowl for Ronnie charity event featuring Eddie Trunk and tons of musical celebrities & more!  PLUS ‘This Week in Rock & Roll History Trivia', Rock Birthdays, ‘The Best & Worst Rock Album Artwork of the Week' & so much more!Everything is up at www.rocknewsweekly.com / All socials & TikTok @rocknewsweekly Watch us LIVE, chat with us & more…Every Sunday around 2pm PST @ https://www.twitch.tv/rocknewsweeklyWatch all of our videos, interviews & subscribe at Youtube.com/@rocknewsweeklyFollow us online:Instagram.com/rocknewsweeklyFacebook.com/rocknewsweeklyTwitter.com/rocknewsweeklyTikTok.com/@rocknewsweeklyAll of our links are up at www.rocknewsweekly.com every Monday, where you canCheck it out on 8 different platforms (including Amazon Audible & Apple/Google Podcasts) #Rock #News #RockNews #RockNewsWeekly #RockNewsWeeklyPodcast #Podcast #Podcasts #Metal #HeavyMetal #Alt #Alternative #ClassicRock #70s #80s #90s #Indie #Trivia #RockTrivia #RockBirthdays #NewMusic #NewMusicReleases #Sting #ThePolice #StewartCopeland #AndySummers #SexPistols #SteveJones #RonnieJamesDio #BowlForRonnie #Radiohead #Radiohead2025Tour #Deftones #AlabamaShakes #Mudvayne #TheSmiths #MikeJoyce

In this episode I mean to talk about this summers festival season but get sidetracked by the much more interesting/boring discussion depending on your like/dislike of someone grappling with first grade math for 35 minutes as I attempt to get into what the hell live performance royalties are, does anyone ever make any and if you are a covers band....do you need permission and who gets the live mechanicals.....warning, dumb maths incomingsupport the show over at :https://patreon.com/AlanAverillPrimordial on Spotifyhttps://open.spotify.com/artist/0BZr6WHaejNA63uhZZZZek?si=yFFV8ypSSDOESUX62_0TzQsponsored by Metal Blade recordshttps://metalblade.indiemerch.com/promo code AA 2024 for 10% off your orderships worldwideFor info on my work as a booking agent go to:https://www.facebook.com/DragonProductionsOfficialor email alan@dragon-productions.comPrimordial cds/lps available fromhttps://www.metalblade.com/primordial/death metalVERMINOUS SERPENThttps://open.spotify.com/artist/54Wpl9JD0Zn4rhpBvrN2Oa?si=zOjIulHXS5y9lW1YHMhgTAdoomDREAD SOVEREIGN https://open.spotify.com/artist/60HY4pl0nbOrZA6u2QnqDN?si=sxQ5_1htR6G3WIvy1I_wXAgothAPRILMENhttps://open.spotify.com/artist/7GzLO1YJClmN5TvV4A37MJ?si=cRXSk24lQKWSqJG-B8KbWQSupport this show http://supporter.acast.com/agitators-anonymous-the-alan-averill-podcast. Hosted on Acast. See acast.com/privacy for more information.

Amazon Merch announced the roll out of three new products! I've got the royalties and the colors for the new polos, comfort colors, & quarter-zips... as well as some new colors for standard shirts!

It's here! Another Random Clippings episode! In this mini episode, I'll pull articles from my folder of stories that just don't fit anywhere else. Happy Labor Day to my USA listeners!SOURCES“Beam Up the Royalties, Shirley.” The Arizona Republic (Phoenix, Arizona), December 28, 1988. www.newspapers.com.“Citizens Fleeing Jury Seekers.” Princeton Daily Clarion (Princeton, Indiana), January 13, 1983. www.newspapers.com.“Gang of Boys Caught After Prying Open Casket in Old Cemetery Vault.” The News (Paterson, New Jersey), September 30, 1935. www.newspapers.com.“James Beard.” Wikipedia, February 22, 2025. https://en.wikipedia.org/wiki/James_Beard. “Juror Excused Because He Does Not Like Shape of Mrozek's Head.” The Seattle Star (Seattle, Washington), September 24, 1922. www.newspapers.com.“Man Fires at Snake, Shoots Off Big Toe.” San Francisco Bulletin (San Francisco, California), May 30, 1922. www.newspapers.com.“Will Wed Her Benefactor.” The Seattle Star (Seattle, Washington), September 24, 1907. www.newspapers.com.“Wins Bride After Long Court Battle.” The Inter Ocean (Chicago, Illinois), September 20, 1907. www.newspapers.com.“‘Just Returning Radio,' Says Youth In Store.” El Paso Herald-Post (El Paso, Texas), January 11, 1964. www.newspapers.com.SOUND SOURCESAl Jolson. “I'll Say She Does.” www.pixapay.com/music.InspectorJ. “Bell, Candle Damper A (H4n).wav.” November 17, 2017. www.freesound.org.Lucille Hegamin and The Dixie Daisies. “Cold Winter Blues.” www.pixabay.com/music.

On this episode of the Self-Publishing News Podcast, Dan Holloway looks at a new study on US reading habits that shows a 40 percent drop in reading for pleasure between 2003 and 2023, with possible shifts toward digital formats and functional reading. He also covers surprising findings about reading with children, the limited impact of COVID on reading trends, and the growing controversy over Audible's new royalty model. Plus, he highlights Spotify's latest audiobook experiment, a “Follow Along” feature that adds visuals to listening. Sponsors Self-Publishing News is proudly sponsored by Bookvault. Sell high-quality, print-on-demand books directly to readers worldwide and earn maximum royalties selling directly. Automate fulfillment and create stunning special editions with BookvaultBespoke. Visit Bookvault.app today for an instant quote. Self-Publishing News is also sponsored by book cover design company Miblart. They offer unlimited revisions, take no deposit to start work and you pay only when you love the final result. Get a book cover that will become your number-one marketing tool. Find more author advice, tips, and tools at our Self-publishing Author Advice Center, with a huge archive of nearly 2,000 blog posts and a handy search box to find key info on the topic you need. And, if you haven't already, we invite you to join our organization and become a self-publishing ally. About the Host Dan Holloway is a novelist, poet, and spoken word artist. He is the MC of the performance arts show The New Libertines, He competed at the National Poetry Slam final at the Royal Albert Hall. His latest collection, The Transparency of Sutures, is available on Kindle.

In this episode, we delve into Elemental Altus Royalties' impressive Q2 financial performance, spotlighting their robust cash generation strategies. David Baker, CFO of the company, walks listeners through the key highlights of the quarter and also shares on insights on year-end guidance at these elevated gold prices.

See omnystudio.com/listener for privacy information.

David Baker CFO of Elemental Altus Royalties (TSX.V:ELE) (OTCQX:ELEMF), joins me to review Q2 2025 financials, record operating cashflows, and outsized year so far of one-off payments. We also dive into a variety of royalty partner project updates, the development growth still on tap in their portfolio of royalties, and look ahead to future acquisitions.   Financial Highlights   Royalty revenue of US$9.1 million and adjusted revenue1 of US$10.5 million, up 102% on Q2 2024 Record Operating Cash Flow plus Caserones dividends of US$14.4 million, up +900% on Q2 2024 Attributable Gold Equivalent Ounces ("GEOs") of 3,184 ounces, up 73% on Q2 2024 and adjusted EBITDA of US$8.8 million, up 155% on Q2 2024 Revenue guidance increased to US$35 million to US$40 million, based on an updated US$3,000/oz gold price for 2025 US$19.7 million increase in cash in Q2 2025   Outlook   Elemental Altus remains on track to meet record guidance of 11,600 to 13,200 GEOs, translating to increased record adjusted revenue of US$35 million to US$40 million, based on a gold price of US$3,000/oz. Production is anticipated to be weighted towards the first half of the year, driven by first gold sales from the Korali-Sud royalty This guidance represents a 38% increase in GEOs and 74% year-on-year increase in adjusted revenue at the mid-point of guidance, with full exposure to higher gold prices Elemental Altus has a Normal Course Issuer Bid ("NCIB") in place to purchase up to 12,288,129 common shares in the capital of the Company   Dave and I then do a rapid-fire review of a number of royalty partner updates at Karlawinda, Caserones Korali-Sud (Diba), Bonikro, Wahgnion, Laverton, Cactus, and Mactung;  each with compelling advancement and growth opportunities.     Turning to the financial strength of Elemental Altus, Dave highlights the US$27 million in cash on hand at quarter's end, the increased revenue guidance of over US$35 million this year, upwards of US$20 million in one-off payments coming in over 2025, the $50 million credit facility on hand, and the solid strategic investor and financial backing from Tether Investments.  All of these factors position the company to review making accretive future acquisition transactions this year and moving forward.     If you have any follow up questions for Dave regarding Elemental Altus Royalties, then please email them to me at Shad@kereport.com.   In full disclosure, Shad is a shareholder of Elemental Altus Royalties at the time of this recording, and may choose to buy or sell shares at any time.   Click here to view recent news on the Elemental Altus Royalties website

En 1988, una canción sin beat, sin instrumentos y grabada en casa alcanzó el #1 en Billboard y ganó tres Grammys: "Don't Worry, Be Happy". ¿Casualidad o estrategia? En este episodio analizamos el “caso McFerrin”, cómo una anomalía rompió las reglas del pop de los 80 y, gracias a la sincronización en “Cocktail”, la conexión emocional y una apuesta de diferenciación (océano azul), terminó conquistando el sistema. Hablamos de propiedad concentrada y royalties, de minimalismo que maximiza margen y de por qué en 2025 —entre TikTok y las playlists por estado de ánimo— lo distinto puede llegar a ser más rentable que competir.

EnWave Corporation CEO Brent Charleton joined Steve Darling from Proactive to announce that the company has successfully closed a fully subscribed private placement, raising $3 million in gross proceeds. The financing will be directed toward the fabrication of two large-scale Radiant Energy Vacuum (REV™) dehydration machines, with capacities ranging from 60kW to 120kW. Charleton explained that the manufacturing process for these machines takes approximately six months to complete, and the investment will allow EnWave to accelerate order fulfillment timelines while supporting anticipated growth in future demand. With its sales pipeline continuing to expand, management sees this strategic investment as a way to strengthen its ability to respond quickly to both existing and prospective customers. In addition to the financing update, EnWave reported interim financial results for the third quarter ended June 30, 2025. The company posted a modest increase in revenue, reflecting steady operational progress. Key achievements during the quarter included the completion of a 120kW REV™ machine for Procescir of Mexico and the start of fabrication for two 60kW machines sold to MicroDried, EnWave's longest-standing royalty partner. Royalty revenues also rose during the quarter, supported by an expanding roster of royalty partners, increased product sales, and higher capacity utilization of existing REV™ machines. Charleton highlighted that the combination of stronger royalty performance, new partner activity, and the capital investment into large-scale REV™ machine capacity positions EnWave for continued long-term growth. By ensuring timely delivery of new equipment while expanding its global network of royalty partners, the company is reinforcing its competitive edge in the growing food and dehydration technology markets. #proactiveinvestors #enwavecorporation #tsxv #enw #DehydrationTech #VacuumMicrowave #RoyaltyBusinessModel #BluechipClients #FoodTech #BusinessNews #Investing #RadiantEnergyVacuum #Agritech #Procescir #DehydrationTechnology #FoodInnovation #SupplyAgreement #InvestmentNews #ProactiveInvestors #microdried

Reporter Jacob Orledge investigates ND oil royalty losses, while Dr. David Herman explains how new funding could help rural hospitals weather Medicaid cuts.

Caleb Shreve, founder and CEO of Killphonic Rights, is a pioneering advocate for artist empowerment and transparency in the music industry. With a career spanning music production, publishing, and rights management, Caleb has worked with Grammy-winning talent while building a company dedicated to helping independent artists collect the royalties they're owed. His expertise bridges the gap between creative artistry and the often opaque business side of music, making him a leading voice in modernizing rights management and creating fairer revenue models for musicians worldwide.In this episode, we explore how Caleb is challenging the status quo and creating new pathways for indie artists to thrive.Key Takeaways:How “black box” royalties work—and why so much indie artist income goes unclaimed.The role NFTs and user-centric streaming models could play in reshaping music monetization.Practical steps every artist can take to protect their rights and maximize royalty collection.---→ Learn more about Caleb Shreve and Killphonic Rights at killphonicrights.com.Book an Artist Breakthrough Session with the Modern Musician team: https://apply.modernmusician.me/podcast

Dans cet épisode du Podcast Minier, on reçoit Guy Desharnais, vice-président à l'évaluation de projets chez Osisko Gold Royalties. Il nous invite à parler franchement de nos certitudes et à prendre conscience de nos réflexes professionnels. À travers des exemples concrets, il explique les biais cognitifs d'autorité, d'ancrage, de survivance qui peuvent fausser notre jugement dans notre travail et mener à une surévaluation des entreprises d'exploitation. Les critères essentiels lors d'une évaluation de projet sont également abordés. Au-delà des chiffres et des modèles, la discussion porte sur le fait d'oser la remise en question, d'accepter sa vulnérabilité professionnelle et voir au-delà des évidences.

Original Post

A new Japanese report has estimated the earnings of Demon Slayer creator Koyoharu Gotouge, whose royalty income has reportedly reached astronomical figures.With the Demon Slayer manga surpassing 220 million copies in circulation, Gotouge's earnings from royalties are likely immense. At Kadokawa's "World Worldless Manga Contest" panel last year, it was revealed that the royalty income for most manga artists is 10%. Based on this rate, a recent report by Real Sound estimates Gotogue's income from physical comic sales alone to be approximately 10 billion yen (about US$64 million), with digital sales adding even more to that total. This figure also does not even include the ever-expanding economic sphere of the Demon Slayer franchise, which encompasses games, stage plays and merchandise, such as a recent collaboration with convenience store chain FamilyMart that sold 2.4 million items.Support The Podcast!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://creators.spotify.com/pod/show/roose366/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow For More Content &Streams!Science Podcast: ⁠⁠https://open.spotify.com/show/5nFXe9dPeWrMpyObyAlrnF?si=7358d1cf32cb45b7⁠⁠Youtube Gaming: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@RooseJp/videos⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Tiktok: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@podcastonanime

Francois Sieberhagen – Partner, Webber Wentzel SAfm Market Update - Podcasts and live stream

This evening we dive into market movements with Rand Swiss, we speak to Gibs about SA's response to the US tariffs, we speak to Jendamark Automation on how tariffs have already impacted their business, we explore mining royalties with Webber Wentzel, Momentum Wealth sheds light on guaranteed annuities, and we discuss the various questions you should ask before retiring with NMG Benefits. SAfm Market Update - Podcasts and live stream

Django Degree is the founder and CEO of Focus on Words, a book platform that gives authors full ownership of their work, royalties, and audience. He's also the author of “I Hope You Wake Up” and “They Lied To You,” books that dive deep into truth, identity, and how we break free from the systems that shape us. His mission is clear: help authors reclaim their voice, rebuild broken systems, and eventually use the success of that work to fund a city for foster youth and orphans across the country.

Mineral and royalty owners face unique cybersecurity risks that most people never consider. From fraudulent emails requesting banking changes to sophisticated scams targeting royalty payments, cybercriminals increasingly view mineral owners as attractive targets due to their regular income streams and valuable assets. In this essential episode, we break down the most common digital threats facing mineral owners and provide straightforward, non-technical strategies to protect your personal information, financial accounts, and royalty payments. Whether you're tech-savvy or prefer to keep things simple, you'll discover practical steps you can implement immediately to safeguard your mineral income and personal data from online criminals.  As always, links to the resources mentioned in this episode can be found in the show notes at mineralrightspodcast.com.

July 15, 2025 | Are licensing fees required or gatekeeping? In this episode of The Chain, host Nimish Gera, vice president of Biologics at Mythic Therapeutics, and Ian Wilkinson, CEO of Gamma Proteins, discuss accessing antibody discovery technology through licensing fees and royalties—and whether these fees are justified or not. Wilkinson delves into the current landscape of antibody discovery technologies, including if AI-based technology warrants fees, how royalties affect both small companies and big pharma, and his background as one of the first experts in the field who offered purely free-for-service options. He also shares what excites him about antibody engineering and beyond. Links from this episode:  Mythic Therapeutics Gamma Proteins 

Django Degree is the founder and CEO of Focus on Words, a book platform that gives authors full ownership of their work, royalties, and audience. He's also the author of “I Hope You Wake Up” and “They Lied To You,” books that dive deep into truth, identity, and how we break free from the systems that shape us. His mission is clear: help authors reclaim their voice, rebuild broken systems, and eventually use the success of that work to fund a city for foster youth and orphans across the country.

Rob Liefeld returns to the CBH podcast talking about Youngblood hitting its stride, Extreme Studios becomes a hothouse of new series: Brigade, Bloodstrike, and nearly two dozen more, all while he mentors rising talents Dan Fraga, Norm Rapmund and more. Mounting costs inside Image spark sharp discussions with Jim Lee, Todd McFarlane, and Mark Silvestri, nudging Liefeld to open Maximum Press for experiments like Battlestar Galactica and Avengelyne. He talks about his exit from Image and his stint on Marvel's Heroes  Reborn, where his Captain America made headlines amidst Marvel's bankruptcy. Recharged, he launches Awesome Comics, partners with Alan Moore for an Award‑winning Supreme, and joins Golden Age legend Joe Simon to shield Fighting American in court. A family walk through Greek ruins now feeds the mythic spark in Cable, Deadpool, and their Fortnite cameos. Royalties still arrive, proof that owning your stories keeps the dream alive, which is a lesson his friend Robert Kirkman echoes with Walking Dead and Invincible. #RobLiefeld #Youngblood #ExtremeStudios #ImageComics #CreatorRights #HeroesReborn #CaptainAmerica #MaximumPress #AlanMoore #Deadpool Support the show

Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm's broad life sciences strategy has been advancing innovation across the life sciences ecosystem in three key ways: late-stage product financing (Collaboration) and new company creation (Ownership), and non-dilutive financing (Credit and Royalties). He explains how Blackstone is bridging the innovation funding gap through high-conviction partnerships with larger BioPharma and MedTech companies, and targeted investment in late-stage trials.

We welcome in Dan O'Flaherty, CEO of Versamet Royalties, for an introduction of the company and its portfolio of projects, which includes cash-royalties and streams. The company was brought to the market by the likes of Equinox Gold and Sandstorm. Dan shares insights into its strategy and the checklists it needs for adding additional assets to their portfolio.

Welcome to the Squared Circle Podcast! I am your host Marie Shadows, and on this episode, we are thanking the men and unpacking feminsit buzzwords.If you believe in my content and love it, support below! Your follows, shares, and upgrade to a paid membership helps out my brand and community to do more as a one-woman content maker:https://marieshadows.substack.comhttps://youtube.com/squaredcirclepodcasthttps://marieshadows-shop.fourthwall.com/https://buymeacoffee.com/marieshadowshttps://discord.gg/jMpZg5G85VMarie Shadows returns with a fiery editorial on why equality isn't what the media or wrestling fans think it is. From Bully Ray's controversial quote to personal experience inside the locker room, Marie pulls no punches on why merit, value, and gratitude matter more than slogans.

In this interview, I chat with Dan O'Flaherty, CEO of Versamet Royalties, a newly listed royalty company already making waves in the royalty and streaming space. Dan previously led Mavericks Metals, which sold to Triple Flag in 2023, and now he's building Versamet to fill a gap between junior royalty players and the multi‑billion‑dollar majors.   Key Highlights from Our Discussion: Rapid portfolio growth: Nearly US$300M in acquisitions since 2022, growing Versamet's market cap to ~$500M. Cash‑flow focus: From 5,000 GEOs in 2024 to 14–16,000 GEOs by 2026, translating to over $50M in annual revenue at current gold prices. Strategic partners: B2Gold (33%), Sandstorm (25%), and Equinox Gold (13%) as cornerstone shareholders, providing technical strength and deal flow. Balanced growth plan: Blend of near‑term organic growth and ongoing acquisitions. Capital markets strategy: TSX Venture listing in May 2025, with plans to graduate to the TSX and pursue a U.S. listing for broader investor access. Dan also explains: Why Versamet stayed private until cash flow was established How their credit facility and equity strategy are funding growth Why this “mid‑tier gap” in the royalty space creates a unique investment opportunity Please email me with any follow up questions for Dan. My email address is Fleck@kereport.com Click here to visit the Versamet Royalties website. 

Welcome to episode 194 of Growers Daily! We cover: when your plants are ready before the soil is, why (some) farmers should get royalties, and compost tea applications.  We are a Non-Profit! 

Hey hey! Today's we've got CHANDLER BOLT of SelfPublishing.com in the studio to discuss the economics of self-publishing a book.We talk about: - The difference between self publishing and normal publishing. - How much money people make self publishing books. - AI in book publishing, how it's changing (or not changing). - The different forms of monetizing a book: Royalties vs backend. - We go through examples of 10 books and their results. - How Chandler's company did $70,000,000 of revenue so far.Follow Chandler Bolt:

EP:53 - Film Music in Flux: Royalties, AI & the Streaming Shakeup  First Step For Sync? Get Your Music Meta-Data Done Right! - Grab your FREE guide on how to do this here: https://mailchi.mp/839e030188ce/9mc45541ff   

Sean "Diddy" Combs, once a titan of music and media with a billion-dollar empire, is watching his fortune shrink under the crushing weight of mounting legal battles. Federal criminal charges, sprawling civil lawsuits, and high-profile accusations have turned his brand from gold to toxic overnight. Partnerships have been severed, business ventures frozen, and revenue streams throttled as sponsors, artists, and corporations flee the storm. What was once a sprawling Bad Boy kingdom—spanning liquor, fashion, music, and television—now resembles a crumbling fortress under siege. Legal fees alone are bleeding him dry, with elite defense teams billing by the hour while court after court keeps the fire roaring.Behind the scenes, Diddy's vast wealth is being dissected by plaintiffs, prosecutors, and investigators like vultures circling a carcass. Bank accounts are being subpoenaed, assets traced, and shell companies unraveled. Real estate holdings are under scrutiny. Royalties and intellectual property once seen as long-term goldmines are now potential collateral. The lifestyle he once flaunted—private jets, champagne nights, and mogul bravado—has been replaced with a desperate damage control operation. And as new accusers continue to step forward and civil litigation piles higher, it's becoming increasingly clear: Diddy isn't just fighting for his legacy anymore—he's fighting to keep the lights on.to contact me:bobbycapucci@protonmail.com

Sean "Diddy" Combs, once a titan of music and media with a billion-dollar empire, is watching his fortune shrink under the crushing weight of mounting legal battles. Federal criminal charges, sprawling civil lawsuits, and high-profile accusations have turned his brand from gold to toxic overnight. Partnerships have been severed, business ventures frozen, and revenue streams throttled as sponsors, artists, and corporations flee the storm. What was once a sprawling Bad Boy kingdom—spanning liquor, fashion, music, and television—now resembles a crumbling fortress under siege. Legal fees alone are bleeding him dry, with elite defense teams billing by the hour while court after court keeps the fire roaring.Behind the scenes, Diddy's vast wealth is being dissected by plaintiffs, prosecutors, and investigators like vultures circling a carcass. Bank accounts are being subpoenaed, assets traced, and shell companies unraveled. Real estate holdings are under scrutiny. Royalties and intellectual property once seen as long-term goldmines are now potential collateral. The lifestyle he once flaunted—private jets, champagne nights, and mogul bravado—has been replaced with a desperate damage control operation. And as new accusers continue to step forward and civil litigation piles higher, it's becoming increasingly clear: Diddy isn't just fighting for his legacy anymore—he's fighting to keep the lights on.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

What's your intellectual property truly worth when it's on the line? Not what you hope or what you feel, but what courts, investors, and negotiators will actually pay. This episode of Intangiblia dives deep into the high-stakes world of IP valuation, where patents, trademarks, and copyrights transform from abstract legal protections into concrete dollar amounts.We journey through landmark global IP disputes that have defined how creative assets are valued in courtrooms from California to Colombia. The Samsung v. Apple design patent battle set precedent for how much of a product's profit can be attributed to its appearance. Epic Systems v. Tata Consultancy Services revealed the billion-dollar worth of trade secrets when they cross into competitors' hands. Meanwhile, cases like Liffers in Spain demonstrate that even moral rights, the right to be credited for your work, carry financial value that courts will recognize and enforce.The podcast unpacks three essential valuation methodologies that every creator should understand: cost-based (what it took to create), market-based (what others pay for similar assets), and income-based (what future earnings it will generate). Through fascinating case studies across industries, from pharmaceuticals to streaming services, sneakers to smartphones, we see how these approaches play out in real disputes with massive financial implications.Beyond methodology, we explore how valuation strategies differ across borders, with emerging economies like India pushing back against one-size-fits-all licensing rates, and Mexico's courts mandating that IP damages reflect genuine commercial impact. The digital transformation adds another layer of complexity, as shown in Disney v. Redbox, where even access codes carried enforceable intellectual property value.Whether you're protecting your creative work, licensing your technology, or facing infringement, this episode delivers a crucial message: in intellectual property, real power lies not just in registration but in pricing. Because in the world of IP, value isn't what you feel, it's what you can prove.Send us a text

Sean "Diddy" Combs, once a titan of music and media with a billion-dollar empire, is watching his fortune shrink under the crushing weight of mounting legal battles. Federal criminal charges, sprawling civil lawsuits, and high-profile accusations have turned his brand from gold to toxic overnight. Partnerships have been severed, business ventures frozen, and revenue streams throttled as sponsors, artists, and corporations flee the storm. What was once a sprawling Bad Boy kingdom—spanning liquor, fashion, music, and television—now resembles a crumbling fortress under siege. Legal fees alone are bleeding him dry, with elite defense teams billing by the hour while court after court keeps the fire roaring.Behind the scenes, Diddy's vast wealth is being dissected by plaintiffs, prosecutors, and investigators like vultures circling a carcass. Bank accounts are being subpoenaed, assets traced, and shell companies unraveled. Real estate holdings are under scrutiny. Royalties and intellectual property once seen as long-term goldmines are now potential collateral. The lifestyle he once flaunted—private jets, champagne nights, and mogul bravado—has been replaced with a desperate damage control operation. And as new accusers continue to step forward and civil litigation piles higher, it's becoming increasingly clear: Diddy isn't just fighting for his legacy anymore—he's fighting to keep the lights on.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

¿Registraste tu propiedad intelectual? Felicidades, pero ahora viene la verdadera pregunta: ¿cuánto vale realmente? Ya no hablamos en teoría, sino en tribunales, negociaciones y transacciones donde el valor de tus activos intangibles determina tu poder de mercado.Desentrañamos los tres métodos fundamentales que la OMPI reconoce para valorar lo intangible: el basado en costos (¿cuánto invertiste?), el basado en mercado (¿cuánto pagan por algo similar?) y el basado en ingresos (¿cuánto dinero generará?). Pero más allá de la teoría, analizamos casos emblemáticos que han definido cómo se valora la propiedad intelectual en el mundo actual.Desde la batalla épica entre Apple y Samsung por patentes de diseño hasta los conflictos por patentes esenciales entre gigantes tecnológicos, pasando por la valoración de secretos comerciales en Epic vs Tata y derechos digitales en Netflix vs Dragon Media. Cada caso nos revela estrategias, métodos y decisiones judiciales que han cambiado las reglas del juego en industrias enteras. Exploramos también cómo diferentes países, desde México hasta Japón e India, están estableciendo nuevos estándares para valorar lo intangible.Descubrirás que en propiedad intelectual el valor no es abstracto ni sentimental – es metódico, estratégico y cuantificable. Y más importante aún, aprenderás que conocer el verdadero valor de tus activos intangibles puede ser la diferencia entre una negociación exitosa y una oportunidad perdida. Porque en el mundo de la PI, el poder está en saber cuánto vale lo que creaste.

Eagle Royalties and Summit Royalty Corp have entered into a definitive amalgamation agreement in respect of a reverse takeover transaction pursuant to which Summit will go public by way of the takeover of Eagle. New drill results from Kenorland Minerals, NGEx Minerals, and Collective Mining. Kingfisher commences drilling at HWY37. Snowline announced the discovery of a new gold system at Cynthia. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠revival-dash-gold.com⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠equinoxgold.com⁠⁠⁠ Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

Are you a founder thinking about writing a book? This video unpacks how to leverage your expertise for long-term income, going beyond just royalties! Join us as we reveal the secrets to a successful book-writing and publishing journey. In this episode, discover: Why a book is essential for founders: Learn how a book can be a powerful tool for solving real-world problems for people in your business, enhancing credibility, and generating deal flow.Different book types and how to get started: Understand the distinction between a "handbook" and an "idea book," and why a handbook is often the best starting point for experts. You'll hear practical tips on how to use existing content like webinars or speeches, even with AI, to quickly create a book.Publishing strategies: Explore the differences between self-publishing, hybrid, and traditional publishing, and which might be best for you. Find out that while traditional publishers can handle licensing and foreign language rights, promotion ultimately remains your responsibility.The realistic timeline and process: Learn that writing and promoting a solid book takes about a year—six months for writing (starting with a book proposal for market validation) and six months for heavy promotion, often via podcasts.Monetizing your book: Discover that the real money-maker isn't royalties, but rather deal flow and attracting the right clients to your business by providing access to tools and funnels. The importance of thinking about your monetization strategy before you start writing is emphasized.Common mistakes to avoid: Hear about the pitfalls first-time authors often encounter, such as trying to put too much information into one book (instead of a series) and not time-blocking for writing.Don't miss these invaluable insights into turning your expertise into a valuable asset! Like, share, and subscribe for more business strategies. Join the community: For more in-depth strategies and support from Simon Severino and 217+ sprinters, join the Sprint Club at strategysprints.com – try it free for 7 days!

Mining Stock Daily interviews Fred Bell, CEO of Elemental Altus Royalties, discussing the recent acquisition of a majority stake by Tether and its implications for the gold royalty business. The discussion covers the rapid developments leading to this deal, the strategic growth opportunities it presents, and the transformative impact on access to capital. The conversation also touches on the democratization of gold investment through Tether's stable coin and the recent changes in the company's board structure.

Joey Allen, guitarist of Warrant, discussed the band's evolution, business model, and personal growth. He highlighted the band's financial success, averaging 40-60 shows a year, and their lean touring operations. Allen emphasized the importance of responsibility, sobriety, and professionalism, noting the band's maturity and lack of drama. He mentioned the band's recent work with Pearl Drums and their commitment to charity. Allen also touched on the band's past, including demos from the "Dog Eat Dog" era and potential future projects. The conversation also covered the challenges and responsibilities of maintaining a successful band0:00:00 - Intro0:00:20 - Locations, Safety & Riots 0:04:15 - Joey's Hiatus & Coming Back 0:06:34 - How the Band Has Matured 0:08:09 - Band as a Business & Operations0:14:36 - AC DC, Van Halen & David Lee Roth 0:19:18 - Guest Lists, Helping & Entitlement0:22:55 - Sadness, Loss, Money & Purpose 0:25:15 - Sobriety & Band Sounding Tighter 0:26:40 - Warrant Set List & Albums 0:30:05 - Robbie Crane & Jerry Dixon 0:31:55 - Zero Drama Bands & Shows 0:35:45 - Bands with Issues & Low IQs 0:40:45 - Other Opportunities  0:42:27 - Doing Shows & Staying Busy 0:43:40 - Responsibility, Therapy & Self Work 0:49:23 - Performing Great Shows & Playing Tracks 0:52:07 - Poison & Def Leppard & Singers 0:56:35 - Adapting Lifestyles with Age 0:57;35 - Warrant Unreleased Music & Video 1:00:55 - Reflecting Back on Youth 1:02:45 - Skid Row Live & New Singer 1:03:55 - New Warrant & Solo Record  1:06:55 - Dog Eat Dog & Seattle Grunge1:08:02 - Self-Indulgence & Changing Things 1:10:45 - Fairness, Money, Credits & Royalties 1:15:01- Happiness & Values 1:17:45 - David Lee Roth, Jani Lane, AC DC & Pantera 1:20:50 - Online Haters 1:21:30 - Promotions Warrant band website:https://warrantrocks.com/Chuck Shute link tree:https://linktr.ee/chuck_shuteSupport the showThanks for Listening & Shute for the Moon!

This week on the New Music Business podcast, Ari sits down with Oscar Höglund, the co-founder and CEO of Epidemic Sound. Epidemic Sound is a leading music and soundtracking platform for content creators. They have garnered attention for its digital rights model and soundtracking tools that help creators to elevate their content with music, while simultaneously supporting artists financially. Oscar shares insights from his journey launching Epidemic after working with Sweden's renowned Zodiak Television.In their episode, Ari and Oscar unpack critical issues impacting independent artists, including royalty structures, streaming economics, and the evolving landscape of music licensing. They explore Epidemic Sound's unique approach to artist compensation, discuss how digital streaming has pushed music toward playlist-driven consumption, and tackle the creative tension artists face when making commercially viable music. This episode offers an in-depth look at one of the industry's most influential platforms shaping the future of music in content creation.Chapters00:00 The Changing Landscape of Music Royalties06:00 Epidemic Sound: A New Model for Music Distribution12:14 Artist Compensation and Ownership Rights17:46 Innovative Approaches to Music Licensing24:09 The Impact of Epidemic Sound on Independent Artists29:53 Future of Music in the Digital Age42:16 The Evolution of Music Consumption46:21 Negotiating with DSPs and Licensing Rates49:52 The Rise of Epidemic Sound55:31 The Artist's Identity Crisis01:08:01 Future Innovations and AI in Music01:21:12 Becoming a Full-Service Music PlatformEdited and mixed by Ari DavidsMusic by Brassroots DistrictProduced by the team at Ari's TakeOrder the THIRD EDITION of How to Make It in the New Music Business: https://book.aristake.com Hosted on Acast. See acast.com/privacy for more information.

00:00 Intro 06:39 The BEST of Marvel in 2025 so far 1:27:44 The BEST of Indie Comics in 2025 1:51:51 The BEST of DC Comics in 2025 so far 2:29:50 Top 5 Fantastic Four Characters #5-4 2:46:33 Mark Millar Called out by Matt Hollingsworth Over Lack of Royalties on Chrononauts 2:57:36 Diamond's Woes Continue as Penguin Pulls Publishers Away From Them 3:13:19 Joining the PalsVerse - Emily "Mighty" McManus Become a Patron - https://www.patreon.com/thecomicspals?fan_landing=true Subscribe on YouTube - youtube.com/thecomicspals?sub_confirm... Join us on Discord: https://discord.gg/6RAX3sT Watch us LIVE on YouTube every: Thursday at 6 PM EST for Pals Pulls Saturday at 10:15 AM EST for The Comics Pals Pals Previews Uploaded Every Monday at 1PM EST Grab some merch here: https://streamlabs.com/thecomicspals/merch

Interview with Jason Attew, President & CEO of OR RoyaltiesOur previous interview: https://www.cruxinvestor.com/posts/osisko-gold-royalties-tsxor-new-strategy-pays-off-as-share-take-off-6881Recording date: 4th June 2025OR Royalties presents a compelling precious metals investment opportunity following a remarkable financial transformation under CEO Jason Attew's leadership. The company has eliminated $300 million in debt over 19 months while achieving a net cash position, positioning it to capitalize on elevated gold prices and favorable market conditions.Financial Performance and OutlookThe company generated approximately $160 million in operating cash flow during 2024 and projects 40% growth to $220-230 million in 2025, assuming current commodity price levels. This exceptional cash generation stems from operational efficiency, with only 25 full-time employees managing a 195-asset portfolio. OR Royalties maintains a $5 billion market capitalization and completed $300 million in transactions during 2024, representing 10% of the total $3 billion royalty and streaming market.Strategic PositioningOR Royalties differentiates itself through geographic concentration, with 80% of assets and cash flow positioned in tier-one jurisdictions including Canada, the United States, and Australia. This focus significantly reduces geopolitical risk compared to peers with emerging market exposure. The portfolio composition aligns with current market dynamics, featuring 94% precious metals exposure comprising 67% gold and 25% silver.Portfolio OptionalityThe company's 195-asset portfolio includes only 22 currently producing assets, providing substantial embedded growth potential as higher commodity prices incentivize development of previously sub-economic projects. This optionality represents significant value that may accelerate as regulatory improvements streamline permitting processes, particularly in the United States.Investment StrategyManagement employs disciplined capital allocation, targeting transactions between $50-500 million with assets expected to generate returns within five years. The company uses conservative consensus gold pricing of $2,400 per ounce for deal evaluation rather than spot prices, ensuring sustainable risk-adjusted returns. "We price everything off consensus and consensus long-term gold because that is our primary product right now," Attew explained, emphasizing the company's conservative approach.Key Growth CatalystsRecent developments include a 24.4% equity stake and 5% net smelter return royalty in Cariboo Gold's British Columbia project, expected to commence production in 2027. The Spring Valley asset in Nevada awaits environmental approval within six weeks, potentially generating 6,000-7,000 gold equivalent ounces annually for OR Royalties once operational.Market EnvironmentThe precious metals sector benefits from macroeconomic uncertainty, monetary policy dynamics, and structural demand drivers supporting elevated commodity prices. Regulatory improvements, especially in North America, are reducing development timelines and providing greater project certainty. "Running a royalty company in this market is just fabulous, if you've got producers in the portfolio," Attew noted, highlighting favorable current conditions.Investment ConsiderationsOR Royalties offers investors leveraged exposure to precious metals appreciation without operational mining risks. The company's net cash position, strong cash flow generation, and substantial portfolio optionality position it to capitalize on continued precious metals strength while maintaining financial flexibility for accretive acquisitions. The combination of conservative deal evaluation, geographic risk mitigation, and experienced management creates a compelling investment proposition for precious metals exposure in today's market environment.View OR Royalties' company profile: https://www.cruxinvestor.com/companies/osisko-gold-royaltiesSign up for Crux Investor: https://cruxinvestor.com

On This Months Authorship Q&A Call we start with a deep dive into the numbers on our Wheels Book drop + why we're closing the cart! Plus:     •    The Real Payout on Amazon KDP Royalties     •    Total Sold of Audio Course 100% Royalties ;)     •    Book Launch Total     •    Open/Close Cart on Book Drop     •    Self-Publishing vs Literary Agent    •    Changing your Life    •    Why you need a living teacher     •    Starting my Trilogyyyyy    •    + moar QA answers To get into our $20 monthly Authorship portal for tons of resources on self-publishing, go to http://www.mamionami.com/authors Authorship also included in Safehouse, our occult business school, $200 monthly at http://www.mamionami.com/safehouse

Normally a years old social media video might come back to HAUNT you, but for today’s Phone Tap victim, that kind of video might change his life for GOOD!See omnystudio.com/listener for privacy information.

Normally a years old social media video might come back to HAUNT you, but for today’s Phone Tap victim, that kind of video might change his life for GOOD!See omnystudio.com/listener for privacy information.

Fred Bell, CEO of Elemental Altus Royalties, discusses the company's record financial performance, strategic cash management, and future opportunities in the royalty space. The conversation highlights a significant increase in revenue and gold equivalent ounces, the company's strong cash position, and plans for potential acquisitions. Bell emphasizes the importance of being in a position to explore new opportunities without the need for fundraising, and he provides insights into the company's guidance and outlook for the future.

This week on the New Music Business podcast, Ari sits down with Danny Ross, a producer and songwriter based in NYC, a columnist at Forbes, and founder of the largest songwriting camp in the world, Anti Social Camp. Danny's Anti Social Camp brings together over 250 songwriters, producers, and artists to collaborate amongst themselves and with major artists every summer in NYC. Past Anti Social Camp attendees have worked with artists including Jacob Collier, Miranda Lambert, Moby, Nile Rodgers, Kimbra, Andy Grammer, JP Saxe, and Rob Thomas. Brands like TikTok, Spotify, YouTube, Amazon, TIDAL, The Recording Academy, Republic Records, DistroKid, and The MLC are also intricately involved in the Anti Social Camp experience.If you are a songwriter or producer who's ever wondered what goes down at songwriting camps or how to get involved, you're going to learn all about that and more in this episode with Danny Ross. https://www.instagram.com/antisocialcamp/ Get $100 your Anti Social Camp Badge by using the code: ARIANTISOCIALVIP at antisocialcamp.comChapters00:00 The Importance of Reputation in the Music Industry03:02 Understanding Songwriting Camps05:48 The Structure and Dynamics of Songwriting Sessions08:47 The Evolution of the Anti Social Camp12:01 Building Community in New York's Music Scene14:54 The Anti Social Camp Experience17:54 Diverse Genres and Collaboration20:54 The Future of Songwriting Camps31:11 Creative Collaborations in Music Production32:26 Success Stories from the Camp33:44 Understanding Major vs. Indie vs. Self-Releasing Artists38:33 The Financial Landscape of Music Production44:53 Navigating Splits and Royalties in Music47:01 The Ethics of Publishing in the Music Industry52:39 Teaching the Next Generation of Music Creators56:40 The Importance of Community in Music Creation59:01 Defining Success in the New Music BusinessEdited and mixed by Ari DavidsMusic by Brassroots DistrictProduced by the team at Ari's TakeOrder the THIRD EDITION of How to Make It in the New Music Business: https://book.aristake.com Hosted on Acast. See acast.com/privacy for more information.

Chuck Shute and Martin Popoff discuss Popoff's book on Guns N' Roses, highlighting its unique photos and the collaboration with his editor, Dennis. Popoff has written 130 books, with 40% of his income from mail orders. They delve into the band's history, including the challenges of updating books and the impact of grunge on hair metal. Popoff emphasizes Axl Rose's dedication to creativity and the band's evolving sound. They also touch on the band's interactions with other musicians and the enduring influence of Guns N' Roses' music. Martin Popoff discussed his new book on Guns N' Roses, set to release by mid-June, with pre-orders available on Amazon and his website, where he signs and ships copies. He mentioned his prolific YouTube channel, "The Contrarians," and his audio-only podcast, "History and Five Songs with Martin Popoff," which has 308 episodes. Popoff also highlighted his involvement in other podcasts, including an AC/DC podcast with John Gaffney and appearances on Brian Slogale's "100 Most Important Songs" series. Chuck Shute concluded the conversation by thanking Popoff and mentioning the upcoming episode release.0:00:00 - Intro 0:00:20 - New GnR Book & Pics 0:02:05 - Writing Books & Updating Them 0:04:23 - Mailbox Money, Royalties & Best Books 0:06:54 - Guns 'N Roses At 40 0:08:34 - Early Guns 'N Roses, Name & Genre 0:16:55 - Shaking Up Rock, Hair Metal & Grunge 0:21:00 - Use Your Illusions 0:24:20 - Production & Sound of Appetite 0:28:25 - Possible New GnR Album & Izzy 0:30:10 - GnR, Motley Crue & Musical Connections 0:31:50 - Music Scene, Moving to L.A. & Evolution of Streaming 0:35:47 - New Bands, Cult Bands & Standing Out 0:42:28 - Axl Rose, Creativity & Time Lapses 0:45:25 - Tommy Stinson on Axl's Strengths & Weaknesses 0:47:03 - Interviewing Big Rockstars Like Axl & Izzy 0:55:50 - Fan of Hair Metal & Grunge & Evolution of Rock 1:02:03 - New Book, Pre-Ordering, Youtube & Podcast1:03:52 -Outro Martin Popoff website:https://martinpopoff.com/html/bookslistChuck Shute link tree:https://linktr.ee/chuck_shuteSupport the showThanks for Listening & Shute for the Moon!